Patents by Inventor Thomas P. Maduskuie, Jr.

Thomas P. Maduskuie, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190002470
    Abstract: The present invention provides bicyclic azaheterocyclobenzylamines of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: February 22, 2018
    Publication date: January 3, 2019
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, JR.
  • Publication number: 20180346481
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: February 27, 2018
    Publication date: December 6, 2018
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, JR., James D. Rodgers
  • Publication number: 20180312506
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: March 21, 2018
    Publication date: November 1, 2018
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, JR., Nikoo Falahatpisheh
  • Patent number: 10092570
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: October 9, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks, Brent Douty, Chunhong He
  • Patent number: 9957268
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: May 1, 2018
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
  • Patent number: 9944646
    Abstract: The present invention provides bicyclic azaheterocyclobenzylamines of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: April 17, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr.
  • Patent number: 9938294
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: April 10, 2018
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr., James D. Rodgers
  • Publication number: 20170340641
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: August 10, 2017
    Publication date: November 30, 2017
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, JR., Richard B. Sparks, Brent Douty, Chunhong He
  • Patent number: 9815839
    Abstract: The present invention provides N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: November 14, 2017
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Thomas P. Maduskuie, Jr., Richard B. Sparks
  • Patent number: 9730939
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: August 15, 2017
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks, Brent Douty, Chunhong He
  • Publication number: 20170217985
    Abstract: The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: November 21, 2016
    Publication date: August 3, 2017
    Inventors: Andrew P. Combs, Eddy W. Yue, Thomas P. Maduskuie, JR.
  • Publication number: 20170210754
    Abstract: The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: January 5, 2017
    Publication date: July 27, 2017
    Applicants: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, JR., James D. Rodgers
  • Publication number: 20170158689
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: November 17, 2016
    Publication date: June 8, 2017
    Applicant: Incyte Corporation
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
  • Publication number: 20170158696
    Abstract: The present invention provides N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: November 15, 2016
    Publication date: June 8, 2017
    Inventors: Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Thomas P. Maduskuie, Jr., Richard B. Sparks
  • Patent number: 9624241
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: April 18, 2017
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr.
  • Patent number: 9540368
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: January 10, 2017
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, Jr.
  • Patent number: 9533997
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I), which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: January 3, 2017
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, Jr.
  • Publication number: 20160264580
    Abstract: The present invention provides bicyclic azaheterocyclobenzylamines of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: March 9, 2016
    Publication date: September 15, 2016
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, JR.
  • Publication number: 20160159817
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I), which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: February 10, 2016
    Publication date: June 9, 2016
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, JR.
  • Patent number: 9309251
    Abstract: The present invention provides bicyclic azaheterocyclobenzylamines of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: April 12, 2016
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr.